Research and Development

Genomics England has announced a new partnership with US-based sequencing specialist Illumina to develop a platform and knowledge base that …

The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …

Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …

An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …

The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …

An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.Dr Kenneth Bloom will join …

Cancer is one of the greatest health challenges of our time, and a leading cause of death in every corner …

Data from the Organisation for Economic Co-operation and Development (OECD) shows Korea and Israel are investing much more in research …